Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer completes acquisition of Array Biopharma
As Array becomes part of Pfizer, it brings an impressive existing portfolio that includes the approved combined use of BRAFTOVI (encorafenib) and MEKTOVI (binimetinib) for the treatment of
As Array becomes part of Pfizer, it brings an impressive existing portfolio that includes the approved combined use of BRAFTOVI (encorafenib) and MEKTOVI (binimetinib) for the treatment of
The late-stage study called MONARCH 2 met its secondary endpoint of overall survival for Verzenio in combination with the endocrine therapy fulvestrant. The trial involved 669 patients, who
OncoImmunity AS will now become a subsidiary of NEC and operate under the name of NEC OncoImmunity AS. OncoImmunity AS, founded in 2014, is a bioinformatics company dedicated
In the late-stage trial called KEYNOTE-522, Keytruda and chemotherapy combination achieved pathological complete response (pCR) following the neoadjuvant part of the neoadjuvant/adjuvant study regimen. pCR is defined as
AVT02 is a mAb biosimilar to AbbVie’s HUMIRA, which is a leading drug indicated for the treatment of several autoimmune diseases, including (but not limited to) Rheumatoid Arthritis
NeuroSTAT’s FDA Fast Track designation makes NeuroVive eligible, for example, for more frequent meetings and written communication with the FDA, continuous feedback on each section of its New
The committee has recommended the approval of Tecentriq plus chemotherapy (carboplatin and Abraxane [albumin-bound paclitaxel; nab-paclitaxel]) for the initial treatment of adults with metastatic non-squamous non-small cell lung
Under the terms of the agreement, Verastem Oncology shall receive an upfront payment of $5 million USD. Verastem Oncology is also eligible to receive up to an additional
Full Week 48 findings were presented today at the 10th International AIDS Society Conference on HIV Science (IAS 2019) in Mexico City. Kimberly Smith, MD, Head of Global
Ab Initio was a privately held antigen-discovery company based in South San Francisco, California. Antigen design and preparation are the first steps necessary for the discovery of therapeutic